{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:55:31Z","timestamp":1790769331143,"version":"4.1.0"},"publisher-location":"New York, NY","reference-count":43,"publisher":"Springer US","isbn-type":[{"value":"9781071654750","type":"print"},{"value":"9781071654767","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-1-0716-5476-7_18","type":"book-chapter","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:34:23Z","timestamp":1790764463000},"page":"277-295","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tissue Pharmacokinetics of Antisense Oligonucleotides"],"prefix":"10.1007","author":[{"given":"Fang-Ching","family":"Chao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Sten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"B\u00e4ckstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e4r","family":"Matsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Gennemark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"18_CR1","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.bcp.2008.11.005","volume":"77","author":"RZ Yu","year":"2009","unstructured":"Yu RZ, Lemonidis KM, Graham MJ et al (2009) Cross-species comparison of in vivo PK\/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. Biochem Pharmacol 77:910\u2013919. https:\/\/doi.org\/10.1016\/j.bcp.2008.11.005","journal-title":"Biochem Pharmacol"},{"key":"18_CR2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","volume":"87","author":"RS Geary","year":"2015","unstructured":"Geary RS, Norris D, Yu R, Bennett CF (2015) Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev 87:46\u201351. https:\/\/doi.org\/10.1016\/j.addr.2015.01.008","journal-title":"Adv Drug Deliv Rev"},{"key":"18_CR3","doi-asserted-by":"publisher","first-page":"143","DOI":"10.4155\/bio.15.234","volume":"8","author":"L Wang","year":"2016","unstructured":"Wang L, Ji C (2016) Advances in quantitative bioanalysis of oligonucleotide biomarkers and therapeutics. Bioanalysis 8:143\u2013155. https:\/\/doi.org\/10.4155\/bio.15.234","journal-title":"Bioanalysis"},{"key":"18_CR4","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/j.drudis.2018.05.030","volume":"23","author":"S Andersson","year":"2018","unstructured":"Andersson S, Antonsson M, Elebring M et al (2018) Drug metabolism and pharmacokinetic strategies for oligonucleotide- and mRNA-based drug development. Drug Discov Today 23:1733\u20131745.\u2002https:\/\/doi.org\/10.1016\/j.drudis.2018.05.030","journal-title":"Drug Discov Today"},{"key":"18_CR5","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1089\/nat.2014.0506","volume":"24","author":"F Eckstein","year":"2014","unstructured":"Eckstein F (2014) Phosphorothioates, essential components of therapeutic oligonucleotides. Nucleic Acid Ther 24:374\u2013387. https:\/\/doi.org\/10.1089\/nat.2014.0506","journal-title":"Nucleic Acid Ther"},{"key":"18_CR6","doi-asserted-by":"publisher","first-page":"5235","DOI":"10.1093\/nar\/gkaa299","volume":"48","author":"ST Crooke","year":"2020","unstructured":"Crooke ST, Vickers TA, Liang X (2020) Phosphorothioate modified oligonucleotide\u2013protein interactions. Nucleic Acids Res 48:5235\u20135253.\u2002https:\/\/doi.org\/10.1093\/nar\/gkaa299","journal-title":"Nucleic Acids Res"},{"key":"18_CR7","doi-asserted-by":"publisher","first-page":"e13243","DOI":"10.15252\/emmm.202013243","volume":"13","author":"SM Hammond","year":"2021","unstructured":"Hammond SM, Aartsma-Rus A, Alves S et al (2021) Delivery of oligonucleotide-based therapeutics: challenges and opportunities. EMBO Mol Med 13:e13243. https:\/\/doi.org\/10.15252\/emmm.202013243","journal-title":"EMBO Mol Med"},{"key":"18_CR8","doi-asserted-by":"publisher","first-page":"100416","DOI":"10.1016\/j.jbc.2021.100416","volume":"296","author":"ST Crooke","year":"2021","unstructured":"Crooke ST, Liang X-H, Baker BF, Crooke RM (2021) Antisense technology: A review. J Biol Chem 296:100416. https:\/\/doi.org\/10.1016\/j.jbc.2021.100416","journal-title":"J Biol Chem"},{"key":"18_CR9","first-page":"235","volume":"3","author":"PL Iversen","year":"2001","unstructured":"Iversen PL (2001) Phosphorodiamidate morpholino oligomers: favorable properties for sequence-specific gene inactivation. Curr Opin Mol Ther 3:235\u2013238","journal-title":"Curr Opin Mol Ther"},{"key":"18_CR10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/nrd3625","volume":"11","author":"R Kole","year":"2012","unstructured":"Kole R, Krainer AR, Altman S (2012) RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov 11:125\u2013140. https:\/\/doi.org\/10.1038\/nrd3625","journal-title":"Nat Rev Drug Discov"},{"key":"18_CR11","doi-asserted-by":"publisher","first-page":"9026","DOI":"10.1093\/nar\/gkab718","volume":"49","author":"BA Anderson","year":"2021","unstructured":"Anderson BA, Freestone GC, Low A et al (2021) Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides. Nucleic Acids Res 49:9026\u20139041. https:\/\/doi.org\/10.1093\/nar\/gkab718","journal-title":"Nucleic Acids Res"},{"key":"18_CR12","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1089\/nat.2022.0005","volume":"32","author":"L Zhang","year":"2022","unstructured":"Zhang L, Liang X, De Hoyos CL et al (2022) The combination of mesyl-phosphoramidate inter-nucleotide linkages and 2\u2032-O-methyl in selected positions in the antisense oligonucleotide enhances the performance of RNaseH1 active PS-ASOs. Nucleic Acid Ther 32:401\u2013411.\u2002https:\/\/doi.org\/10.1089\/nat.2022.0005","journal-title":"Nucleic Acid Ther"},{"key":"18_CR13","doi-asserted-by":"publisher","first-page":"102133","DOI":"10.1016\/j.omtn.2024.102133","volume":"35","author":"E B\u00e4ckstr\u00f6m","year":"2024","unstructured":"B\u00e4ckstr\u00f6m E, Bonetti A, Johnsson P et al (2024) Tissue pharmacokinetics of antisense oligonucleotides. Mol Ther Nucleic Acids 35:102133.\u2002https:\/\/doi.org\/10.1016\/j.omtn.2024.102133","journal-title":"Mol Ther Nucleic Acids"},{"key":"18_CR14","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.omtn.2016.12.003","volume":"6","author":"Y Huang","year":"2017","unstructured":"Huang Y (2017) Preclinical and clinical advances of GalNAc-decorated nucleic acid therapeutics. Mol Ther Nucleic Acids 6:116\u2013132. https:\/\/doi.org\/10.1016\/j.omtn.2016.12.003","journal-title":"Mol Ther Nucleic Acids"},{"key":"18_CR15","doi-asserted-by":"publisher","first-page":"8796","DOI":"10.1093\/nar\/gku531","volume":"42","author":"TP Prakash","year":"2014","unstructured":"Prakash TP, Graham MJ, Yu J et al (2014) Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res 42:8796\u20138807. https:\/\/doi.org\/10.1093\/nar\/gku531","journal-title":"Nucleic Acids Res"},{"key":"18_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1089\/nat.2018.0753","volume":"29","author":"ST Crooke","year":"2019","unstructured":"Crooke ST, Baker BF, Xia S et al (2019) Integrated assessment of the clinical performance of GalNAc3-conjugated 2\u2032-O-methoxyethyl chimeric antisense oligonucleotide. I. Human volunteer experience. Nucleic Acid Ther 29:16\u201332. https:\/\/doi.org\/10.1089\/nat.2018.0753","journal-title":"Nucleic Acid Ther"},{"key":"18_CR17","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1080\/13506129.2016.1191458","volume":"23","author":"EJ Ackermann","year":"2016","unstructured":"Ackermann EJ, Guo Shuling, Benson MerrillD et al (2016) Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides. Amyloid 23:148\u2013157. https:\/\/doi.org\/10.1080\/13506129.2016.1191458","journal-title":"Amyloid"},{"key":"18_CR18","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/ehf2.13154","volume":"8","author":"NJ Viney","year":"2021","unstructured":"Viney NJ, Guo S, Tai L-J et al (2021) Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data. ESC Heart Fail 8:652\u2013661. https:\/\/doi.org\/10.1002\/ehf2.13154","journal-title":"ESC Heart Fail"},{"key":"18_CR19","doi-asserted-by":"publisher","first-page":"e70076","DOI":"10.1111\/cts.70076","volume":"17","author":"AL Lennox","year":"2024","unstructured":"Lennox AL, Huang F, Behrs MK et al (2024) Imetelstat, a novel, first-in-class telomerase inhibitor: mechanism of action, clinical, and translational science. Clin Transl Sci 17:e70076. https:\/\/doi.org\/10.1111\/cts.70076","journal-title":"Clin Transl Sci"},{"key":"18_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-024-02112-8","volume":"10","author":"M Liu","year":"2025","unstructured":"Liu M, Wang Y, Zhang Y et al (2025) Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines. Signal Transduct Target Ther 10:1\u201357. https:\/\/doi.org\/10.1038\/s41392-024-02112-8","journal-title":"Signal Transduct Target Ther"},{"key":"18_CR21","doi-asserted-by":"publisher","first-page":"eadi2245","DOI":"10.1126\/scitranslmed.adi2245","volume":"16","author":"SJ Barker","year":"2024","unstructured":"Barker SJ, Thayer MB, Kim C et al (2024) Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood-brain barrier. Sci Transl Med 16:eadi2245.\u2002https:\/\/doi.org\/10.1126\/scitranslmed.adi2245","journal-title":"Sci Transl Med"},{"key":"18_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s43856-025-00733-w","volume":"5","author":"T Weeden","year":"2025","unstructured":"Weeden T, Picariello T, Quinn B et al (2025) FORCE platform overcomes barriers of oligonucleotide delivery to muscle and corrects myotonic dystrophy features in preclinical models. Commun Med 5:1\u201318. https:\/\/doi.org\/10.1038\/s43856-025-00733-w","journal-title":"Commun Med"},{"key":"18_CR23","doi-asserted-by":"publisher","first-page":"5901","DOI":"10.1093\/nar\/gkad415","volume":"51","author":"B Malecova","year":"2023","unstructured":"Malecova B, Burke RS, Cochran M et al (2023) Targeted tissue delivery of RNA therapeutics using antibody\u2013oligonucleotide conjugates (AOCs). Nucleic Acids Res 51:5901\u20135910. https:\/\/doi.org\/10.1093\/nar\/gkad415","journal-title":"Nucleic Acids Res"},{"key":"18_CR24","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s10928-014-9398-5","volume":"42","author":"R Shimizu","year":"2015","unstructured":"Shimizu R, Kitade M, Kobayashi T et al (2015) Pharmacokinetic\u2013pharmacodynamic modeling for reduction of hepatic apolipoprotein B mRNA and plasma total cholesterol after administration of antisense oligonucleotide in mice. J Pharmacokinet Pharmacodyn 42:67\u201377. https:\/\/doi.org\/10.1007\/s10928-014-9398-5","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"18_CR25","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/978-1-4939-9670-4_19","volume-title":"Oligonucleotide-based therapies: methods and protocols","author":"R Jansson-L\u00f6fmark","year":"2019","unstructured":"Jansson-L\u00f6fmark R, Ahlstr\u00f6m C, Gennemark P (2019) ADME: assessing pharmacokinetic\u2013pharmacodynamic parameters of oligonucleotides. In: Gissberg O, Zain R, Lundin KE (Eds.)Eds. Oligonucleotide-based therapies: methods and protocols. Springer, New York, NY, 317\u2013339"},{"key":"18_CR26","doi-asserted-by":"publisher","first-page":"452","DOI":"10.3109\/08958378.2014.907587","volume":"26","author":"RA Fey","year":"2014","unstructured":"Fey RA, Templin MV, McDonald JD et al (2014) Local and systemic tolerability of a 2\u2019O-methoxyethyl antisense oligonucleotide targeting interleukin-4 receptor-\u03b1 delivery by inhalation in mouse and monkey. Inhal Toxicol 26:452\u2013463. https:\/\/doi.org\/10.3109\/08958378.2014.907587","journal-title":"Inhal Toxicol"},{"key":"18_CR27","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1023\/A:1011934011690","volume":"15","author":"PL Nicklin","year":"1998","unstructured":"Nicklin PL, Bayley D, Giddings J et al (1998) Pulmonary bioavailability of a phosphorothioate oligonucleotide (CGP 64128A): comparison with other delivery routes. Pharm Res 15:583\u2013591. https:\/\/doi.org\/10.1023\/A:1011934011690","journal-title":"Pharm Res"},{"key":"18_CR28","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1124\/jpet.112.197426","volume":"343","author":"TA Zanardi","year":"2012","unstructured":"Zanardi TA, Han S-C, Jeong EJ et al (2012) Pharmacodynamics and subchronic toxicity in mice and monkeys of ISIS 388626, a second-generation antisense oligonucleotide that targets human sodium glucose cotransporter 2. J Pharmacol Exp Ther 343:489\u2013496. https:\/\/doi.org\/10.1124\/jpet.112.197426","journal-title":"J Pharmacol Exp Ther"},{"key":"18_CR29","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1089\/nat.2013.0422","volume":"23","author":"SA Burel","year":"2013","unstructured":"Burel SA, Han S-R, Lee H-S et al (2013) Preclinical evaluation of the toxicological effects of a novel constrained ethyl modified antisense compound targeting signal transducer and activator of transcription 3 in mice and cynomolgus monkeys. Nucleic Acid Ther 23:213\u2013227. https:\/\/doi.org\/10.1089\/nat.2013.0422","journal-title":"Nucleic Acid Ther"},{"key":"18_CR30","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1177\/01926233231178282","volume":"51","author":"JM Monn\u00e9 Rodr\u00edguez","year":"2023","unstructured":"Monn\u00e9 Rodr\u00edguez JM, Frisk A-L, Kreutzer R et al (2023) European Society of Toxicologic Pathology (Pathology 2.0 Molecular Pathology Special Interest Group): review of in situ hybridization techniques for drug research and development. Toxicol Pathol 51:92\u2013111. https:\/\/doi.org\/10.1177\/01926233231178282","journal-title":"Toxicol Pathol"},{"key":"18_CR31","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41573-021-00162-z","volume":"20","author":"ST Crooke","year":"2021","unstructured":"Crooke ST, Baker BF, Crooke RM, Liang X (2021) Antisense technology: an overview and prospectus. Nat Rev Drug Discov 20:427\u2013453. https:\/\/doi.org\/10.1038\/s41573-021-00162-z","journal-title":"Nat Rev Drug Discov"},{"key":"18_CR32","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1177\/1091581811403505","volume":"30","author":"P Sazani","year":"2011","unstructured":"Sazani P, Ness KPV, Weller DL et al (2011) Repeat-dose toxicology evaluation in cynomolgus monkeys of AVI-4658, a phosphorodiamidate morpholino oligomer (PMO) drug for the treatment of Duchenne muscular dystrophy. Int J Toxicol 30:313\u2013321. https:\/\/doi.org\/10.1177\/1091581811403505","journal-title":"Int J Toxicol"},{"key":"18_CR33","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s40262-014-0224-4","volume":"54","author":"RS Geary","year":"2015","unstructured":"Geary RS, Baker BF, Crooke ST (2015) Clinical and preclinical pharmacokinetics and pharmacodynamics of Mipomersen (Kynamro\u00ae): a second-generation antisense oligonucleotide inhibitor of apolipoprotein B. Clin Pharmacokinet 54:133\u2013146. https:\/\/doi.org\/10.1007\/s40262-014-0224-4","journal-title":"Clin Pharmacokinet"},{"key":"18_CR34","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1124\/dmd.106.012401","volume":"35","author":"RZ Yu","year":"2007","unstructured":"Yu RZ, Kim T-W, Hong A et al (2007) Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab Dispos 35:460\u2013468. https:\/\/doi.org\/10.1124\/dmd.106.012401","journal-title":"Drug Metab Dispos"},{"key":"18_CR35","doi-asserted-by":"publisher","first-page":"eabe9117","DOI":"10.1126\/scitranslmed.abe9117","volume":"13","author":"P Gennemark","year":"2021","unstructured":"Gennemark P, Walter K, Clemmensen N et al (2021) An oral antisense oligonucleotide for PCSK9 inhibition. Sci Transl Med 13:eabe9117. https:\/\/doi.org\/10.1126\/scitranslmed.abe9117","journal-title":"Sci Transl Med"},{"key":"18_CR36","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10928-006-9035-z","volume":"34","author":"P Jacqmin","year":"2007","unstructured":"Jacqmin P, Snoeck E, van Schaick EA et al (2007) Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K\u2013PD model. J Pharmacokinet Pharmacodyn 34:57\u201385. https:\/\/doi.org\/10.1007\/s10928-006-9035-z","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"18_CR37","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1023\/a:1018943613122","volume":"10","author":"B Davies","year":"1993","unstructured":"Davies B, Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093\u20131095. https:\/\/doi.org\/10.1023\/a:1018943613122","journal-title":"Pharm Res"},{"key":"18_CR38","doi-asserted-by":"crossref","unstructured":"ICRP (2002) Basic anatomical and physiological data for use in radiological protection reference values. ICRP Publication 89. Ann. ICRP 32 (3-4)","DOI":"10.1016\/S0146-6453(03)00002-2"},{"key":"18_CR39","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10928-025-09980-9","volume":"52","author":"A Derbalah","year":"2025","unstructured":"Derbalah A, Stader F, Liu C et al (2025) Cross-species translational modelling of targeted therapeutic oligonucleotides using physiologically based pharmacokinetics. J Pharmacokinet Pharmacodyn 52:35. https:\/\/doi.org\/10.1007\/s10928-025-09980-9","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"18_CR40","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s10928-021-09761-0","volume":"48","author":"M Monine","year":"2021","unstructured":"Monine M, Norris D, Wang Y, Nestorov I (2021) A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration. J Pharmacokinet Pharmacodyn 48:639\u2013654. https:\/\/doi.org\/10.1007\/s10928-021-09761-0","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"18_CR41","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.ejpb.2018.11.005","volume":"133","author":"MJR Ruigrok","year":"2018","unstructured":"Ruigrok MJR, Xian J-L, Frijlink HW et al (2018) siRNA-mediated protein knockdown in precision-cut lung slices. Eur J Pharm Biopharm 133:339\u2013348. https:\/\/doi.org\/10.1016\/j.ejpb.2018.11.005","journal-title":"Eur J Pharm Biopharm"},{"key":"18_CR42","doi-asserted-by":"publisher","first-page":"273","DOI":"10.14573\/altex.2108241","volume":"39","author":"D Ramsden","year":"2022","unstructured":"Ramsden D, Belair DG, Agarwal S et al (2022) Leveraging microphysiological systems to address challenges encountered during development of oligonucleotide therapeutics. Altern Anim Exp 39:273\u2013296. https:\/\/doi.org\/10.14573\/altex.2108241","journal-title":"Altern Anim Exp"},{"key":"18_CR43","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/s41551-023-01154-7","volume":"8","author":"DM Stresser","year":"2024","unstructured":"Stresser DM, Kopec AK, Hewitt P et al (2024) Towards in vitro models for reducing or replacing the use of animals in drug testing. Nat Biomed Eng 8:930\u2013935. https:\/\/doi.org\/10.1038\/s41551-023-01154-7","journal-title":"Nat Biomed Eng"}],"container-title":["Methods in Molecular Biology","Gapmers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-5476-7_18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:02:07Z","timestamp":1790766127000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-5476-7_18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9781071654750","9781071654767"],"references-count":43,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-5476-7_18","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"1 October 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"Funding","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this chapter.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conflict of Interest","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"FCC, SS, EB, and PG are employees of AstraZeneca and hold ownership, options, and\/or interests in AstraZeneca stock.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}}]}}